Heat plot for the decision curve analysis, in a range of threshold values.
The same threshold is assumed for dimethyl fumarate (DF) and glatiramer
acetate (GA) (4%–25%). The threshold values for natalizumab range between
19% and 40%. The plot shows which approach has the highest net benefit
between all possible approaches: (a) treat all patients with placebo, (b)
treat all patients with natalizumab (N), (c) treat all patients with
dimethyl fumarate, (d) treat all patients with glatiramer acetate, and (e)
treat patients based on the prediction model. The empty gray cells present
the threshold value combinations that are not clinically possible. The
numbers in the cells are differences in net benefit (NB) between the 2
strategies. When the “treat patients based on the prediction model” strategy
is the best, the number in the cell (i.e., red cells) is the difference
between its NB and the NB of the second-best strategy. Otherwise, we present
the difference between the NB of the best strategy and the NB of the “treat
patients based on the prediction model” strategy. The presented NB
estimations are multiplied by 100.